What Researchers Did
Researchers reported on a case where hyperbaric oxygen therapy successfully treated a 63-year-old woman with severe livedoid vasculopathy that had not responded to other treatments.
What They Found
A 63-year-old female patient with refractory livedoid vasculopathy, also having an MTHFR gene polymorphism, received hyperbaric oxygen therapy at 2.0 absolute atmosphere for 120 minutes, three times a week. After 4 sessions, her painful ulcers began to heal, and after 13 sessions, the skin lesions were almost completely healed. During an eight-month follow-up, the ulcers did not recur, and her symptoms remained stable.
What This Means for Canadian Patients
For Canadian patients suffering from severe, treatment-resistant livedoid vasculopathy, this case suggests hyperbaric oxygen therapy might be a potential treatment option. It offers hope for those with painful ulcers that have not improved with standard therapies, potentially leading to wound healing and symptom stability.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This study is a single case report, which means its findings may not apply to all patients with livedoid vasculopathy.